Evidence map›Paper›PMID 33947039›Full record

ReviewCells2021

HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases.

Fabrizia Bonacina, Angela Pirillo, Alberico L Catapano, Giuseppe D Norata

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Fabrizia BonacinaDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-2611-1177
Angela PirilloCenter for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, 20092 Milan, Italy.ORCID 0000-0002-2948-6257
Alberico L CatapanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-7593-2094
Giuseppe D NorataDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-6081-1257
University of Milan · ITMultiMedica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High density lipoproteins (HDL) are heterogeneous particles composed by a vast array of proteins and lipids, mostly recognized for their cardiovascular (CV) protective effects. However, evidences from basic to clinical research have contributed to depict a role of HDL in the modulation of immune-inflammatory response thus paving the road to investigate their involvement in other diseases beyond those related to the CV system. HDL-C levels and HDL composition are indeed altered in patients with autoimmune diseases and usually associated to disease severity. At molecular levels, HDL have been shown to modulate the anti-inflammatory potential of endothelial cells and, by controlling the amount of cellular cholesterol, to interfere with the signaling through plasma membrane lipid rafts in immune cells. These findings, coupled to observations acquired from subjects carrying mutations in genes related to HDL system, have helped to elucidate the contribution of HDL beyond cholesterol efflux thus posing HDL-based therapies as a compelling interventional approach to limit the inflammatory burden of immune-inflammatory diseases.

Indexed as

AnimalsCardiovascular DiseasesHumansImmune System DiseasesImmunity, InnateLipoproteins, HDLLymphocytesMacrophagesLipoproteins, HDLautoimmune diseasecholesterol effluxhigh density lipoproteinimmune-inflammatory response

Identifiers

PMID33947039
PMCPMC8146776
OpenAlexW3159756909

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.